Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $395,575.45 in Stock

Key Points

• Pharvaris director Viviane Monges sold 11,969 shares for approximately $395,575, reducing her holdings by 68.52% to 5,500 shares.
• PHVS shares fell 2.3% to $32.22 during Friday trading. The company recently reported an adjusted loss of $0.81 per share, below the $0.75-loss analyst consensus.
• Wall Street remains broadly optimistic, with a consensus “Moderate Buy” rating and an average price target of $59.87, while several institutional investors recently established or expanded positions.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) Director Viviane Monges sold 11,969 shares of the company's stock in a transaction dated Wednesday, September 23rd. The stock was sold at an average price of $33.05, for a total value of $395,575.45. Following the sale, the director owned 5,500 shares of the company's stock, valued at $181,775. This represents a 68.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pharvaris Trading Down 2.3%

Shares of PHVS traded down $0.78 during midday trading on Friday, reaching $32.22. 271,150 shares of the company were exchanged, compared to its average volume of 417,060. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -10.58 and a beta of -2.33. Pharvaris N.V. has a 1-year low of $20.65 and a 1-year high of $43.25. The stock has a 50-day moving average price of $35.35 and a 200-day moving average price of $31.98.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Equities research analysts anticipate that Pharvaris N.V. will post -3.12 earnings per share for the current year.

Institutional Investors Weigh In On Pharvaris

Several large investors have recently added to or reduced their stakes in PHVS. venBio Partners LLC acquired a new stake in shares of Pharvaris in the second quarter valued at approximately $160,569,809. 5AM Venture Management LLC acquired a new position in shares of Pharvaris during the second quarter worth approximately $27,581,008. BlackRock Inc. acquired a new position in shares of Pharvaris during the second quarter worth approximately $26,677,000. Elmind Capital LP bought a new position in Pharvaris in the 2nd quarter worth approximately $18,180,435. Finally, Seven Fleet Capital Management LP grew its holdings in Pharvaris by 144.6% in the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company's stock worth $26,782,000 after buying an additional 457,804 shares in the last quarter.

Wall Street Analysts Forecast Growth

PHVS has been the subject of several research analyst reports. Wedbush boosted their price objective on Pharvaris from $42.00 to $50.00 and gave the company an "outperform" rating in a report on Wednesday, September 9th. HC Wainwright reiterated a "buy" rating and issued a $60.00 target price on shares of Pharvaris in a research report on Tuesday, September 8th. Morgan Stanley boosted their price target on Pharvaris from $46.00 to $62.00 and gave the company an "overweight" rating in a report on Wednesday, September 9th. Rosenblatt Securities set a $60.00 price objective on Pharvaris in a research note on Wednesday, September 9th. Finally, UBS Group set a $79.00 price objective on shares of Pharvaris in a report on Wednesday, September 9th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Pharvaris currently has a consensus rating of "Moderate Buy" and a consensus target price of $59.87.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.